A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer

Trial Profile

A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2018

At a glance

  • Drugs Gemcitabine (Primary) ; Olaratumab (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 23 Apr 2018 Planned End Date changed from 1 Oct 2020 to 31 May 2022.
    • 23 Apr 2018 Planned primary completion date changed from 2 Dec 2019 to 17 Oct 2020.
    • 18 Jan 2018 According to trial design presented at the 2018 Gastrointestinal Cancers Symposium, approx. 162 patients will be randomised in phase II part of this study and as of Sep 2017, this study was enrolling patient for phase I part of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top